ZyVersa Therapeutics, Inc. (ZVSA)
OTCMKTS · Delayed Price · Currency is USD
0.1920
-0.0180 (-8.57%)
At close: Apr 14, 2026

ZyVersa Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
0.11.533.145.90.33
Cash & Short-Term Investments
0.11.533.145.90.33
Cash Growth
-93.35%-51.21%-46.84%1696.27%88.11%
Prepaid Expenses
0.230.180.220.230.11
Other Current Assets
0.01--0.240.38
Total Current Assets
0.351.723.356.360.81
Property, Plant & Equipment
--0.010.120.03
Goodwill
---11.9-
Other Intangible Assets
-18.6518.65100.09-
Long-Term Deferred Charges
-0.06---
Other Long-Term Assets
-0.180.10.050.29
Total Assets
0.3520.622.11118.511.13
Accounts Payable
10.129.348.436.032
Accrued Expenses
2.551.891.250.80.75
Current Portion of Long-Term Debt
----9.15
Current Portion of Leases
--0.010.11-
Current Income Taxes Payable
---0.11-
Other Current Liabilities
0.060.010.511.151.73
Total Current Liabilities
12.7311.2310.198.1913.63
Long-Term Deferred Tax Liabilities
-0.850.8410.32-
Other Long-Term Liabilities
---0.330.33
Total Liabilities
12.7312.0811.0418.8413.96
Common Stock
00000
Additional Paid-In Capital
125.2121.16114.3104.5840.07
Retained Earnings
-137.58-112.63-103.22-4.92-52.9
Treasury Stock
-0.01-0.01-0.01--
Total Common Equity
-12.398.5211.0799.66-12.83
Shareholders' Equity
-12.398.5211.0799.66-12.83
Total Liabilities & Equity
0.3520.622.11118.511.13
Total Debt
--0.010.119.15
Net Cash (Debt)
0.11.533.135.79-8.82
Net Cash Growth
-93.35%-51.07%-45.99%--
Net Cash Per Share
0.021.3832.090.25-3.65
Filing Date Shares Outstanding
8.12.570.830.1224.17
Total Common Shares Outstanding
8.12.510.410.0324.17
Working Capital
-12.39-9.52-6.84-1.83-12.81
Book Value Per Share
-1.533.4027.333868.91-0.53
Tangible Book Value
-12.39-10.13-7.57-12.32-12.83
Tangible Book Value Per Share
-1.53-4.04-18.69-478.20-0.53
Machinery
--0.050.050.05
Source: S&P Global Market Intelligence. Standard template. Financial Sources.